Avacta Group Plc (FRA:RTQ1)

Market Cap	260.12M +17.9%
Revenue (ttm)	131.83K -96.0%
Net Income	-73.03M
EPS	-0.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	250
Open	0.6100
Previous Close	0.6200
Day's Range	0.6100 - 0.6100
52-Week Range	0.2920 - 0.9100
Beta	n/a
RSI	39.64
Earnings Date	Jan 5, 2026

About Avacta Group

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that driv...

• Industry: Commercial Physical and Biological Research
• Founded: 2003
• Employees: 151
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RTQ1

Financial Performance

In 2024, Avacta Group's revenue was 113,000, a decrease of -96.04% compared to the previous year's 2.85 million. Losses were -52.84 million, 58.9% more than in 2023.

Financial numbers in GBP